Kristina Unnebrink

Ludwigshafen University of Business and Society — Germany

Immunology and Microbiology · Life Sciences

30h-index4.1kcitations82works3.62yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Psoriasis: Treatment and Pathogenesis(15), Dermatology and Skin Diseases(14), Autoimmune and Inflammatory Disorders Research(14), Rheumatoid Arthritis Research and Therapies(13), Health Systems, Economic Evaluations, Quality of Life(8)

Publications79 total

ITCC-101/APAL2020D: A randomized Phase 3 trial of fludarabine/cytarabine/gemtuzumab ozogamycin with or without venetoclax in children with relapsed Acute Myeloid Leukemia
Blood·2025Open Access
Venetoclax Combined With Chemotherapy in Pediatric and Adolescent/Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
Universität Zürich, ZORA·2025Open Access
Venetoclax Alone or in Combination With Chemotherapy in Paediatric and Adolescent/Young Adult Patients With Relapsed/Refractory Acute Myeloid Leukaemia
Pediatric Blood & Cancer·2025· 1 citedOpen Access
Venetoclax Combined With Chemotherapy in Pediatric and Adolescent/Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
Pediatric Blood & Cancer·2025· 9 cited
Pharmacokinetics, Safety, Tolerability, and Exploratory Efficacy of Upadacitinib in Children with Severe Atopic Dermatitis
Clinical Therapeutics·2024· 8 citedOpen Access
OP0164 SAFETY AND EFFICACY OF UPADACITINIB FOR PEDIATRIC PATIENTS WITH POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS: AN INTERIM ANALYSIS OF AN OPEN-LABEL, PHASE 1 TRIAL
Annals of the Rheumatic Diseases·2023· 3 citedOpen Access
ITCC-101/APAL2020D: A Randomized Phase 3 Trial of Fludarabine/Cytarabine/Gemtuzumab Ozogamycin with or without Venetoclax in Children with Relapsed Acute Myeloid Leukemia
Blood·2022· 6 cited
Less Invasive Surfactant Administration: A Review of Current Evidence of Clinical Outcomes With Beractant
Cureus·2022· 1 citedOpen Access
Direct comparison of risankizumab and fumaric acid esters in systemic therapy–naïve patients with moderate-to-severe plaque psoriasis: a randomized controlled trial
British Journal of Dermatology·2021· 19 citedOpen Access
Patient‐reported outcomes with risankizumab versus fumaric acid esters in systemic therapy‐naïve patients with moderate to severe plaque psoriasis: a phase 3 clinical trial
Journal of the European Academy of Dermatology and Venereology·2021· 23 citedOpen Access
Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia Harboring Heterogeneous Genomic Profiles Respond to Venetoclax in Combination with Chemotherapy
Blood·2020· 14 cited
Venetoclax Alone or in Combination with Chemotherapy: Responses in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia with Heterogeneous Genomic Profiles
Blood·2020· 9 cited
The Early vs. Late Infantile Strabismus Surgery Study: First Results
2020
The first report of pediatric patients with solid tumors treated with venetoclax.
Journal of Clinical Oncology·2020· 5 cited
Beractant and poractant alfa in premature neonates with respiratory distress syndrome: a systematic review of real-world evidence studies and randomized controlled trials
Journal of Perinatology·2020· 24 citedOpen Access
Safety, Efficacy, and PK of the BCL2 Inhibitor Venetoclax in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Phase 1 Study
Blood·2019· 16 cited
SAFETY AND EFFICACY OF PALIVIZUMAB IN CHILDREN AT HIGH RISK OF SEVERE RESPIRATORY SYNCYTIAL VIRAL INFECTION IN RUSSIA AND BELARUS
PEDIATRIA Journal named after G N SPERANSKY·2019· 1 citedOpen Access
Sustained long‐term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double‐blind, phase <scp>III</scp> study
British Journal of Dermatology·2019· 40 citedOpen Access
Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low‐dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis
Journal of Viral Hepatitis·2019· 5 citedOpen Access
On estimands and the analysis of adverse events in the presence of varying follow‐up times within the benefit assessment of therapies
Pharmaceutical Statistics·2018· 8 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

H. Küpper(8), Diamant Thaçi(8), Kim Papp(5), Richard G. Langley(5), S. Kary(5), Seth E. Karol(5), Gerd R Burmester(4), Frank G. Holz(4), Todd M. Cooper(4), Andrew E. Place(4), J.‐P. Ortonne(3), Jürgen Windeler(3), Kristian Reich(3), Pierre‐Dominique Ghislain(3), David Williams(3), Wendell C. Valdecantos(3), Orin M. Goldblum(3), Andreas Pinter(3), Simone Rubant(3), Maureen M. O’Brien(3)